Alemtuzumab-induced remission of multiple sclerosis-associated uveitis
Author:
Funder
National Institute for Health Research
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology
Link
http://link.springer.com/article/10.1007/s10792-016-0370-9/fulltext.html
Reference19 articles.
1. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828. doi: 10.1016/s0140-6736(12)61769-3
2. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD-D, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DAS (2011) Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 10(4):338–348. doi: 10.1016/s1474-4422(11)70020-5
3. Coles AJC, Compston DA, Selmaj KW et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359(17):1786–1801
4. Hale G (2001) The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 3(3):137–143. doi: 10.1080/146532401753174098
5. Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, Shankara S, Roberts BL, Kaplan JM (2012) Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 7(6):e39416. doi: 10.1371/journal.pone.0039416
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Anti‐CD20 therapy for multiple sclerosis‐associated uveitis: A case series;European Journal of Neurology;2022-07-13
2. A Comprehensive Update on Retinal Vasculitis: Etiologies, Manifestations and Treatments;Journal of Clinical Medicine;2022-04-30
3. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis;Journal of Ocular Pharmacology and Therapeutics;2022-04-01
4. An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma;Eye;2022-01-01
5. Biologics in Uveitis;Handbook of Biologics for Rheumatological Disorders;2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3